DailyStocks Stock Article Search

https://www.fool.com/investing/2023/12/31/eli-lilly-stock-jumped-59-in-2023-is-it-a-good-sto/?source=iedfolrf0000001 Dec 31, 2023 - Sales of its new weight-management drug could be off the charts next year. 0

https://www.zacks.com/stock/news/2203352/eli-lilly-lly-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2203352 Dec 28, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close. 0

https://www.zacks.com/stock/news/2202432/is-spdr-msci-usa-strategicfactors-etf-qus-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2202432 Dec 27, 2023 - Smart Beta ETF report for QUS 0

https://www.fool.com/investing/2023/12/22/can-this-red-hot-stock-beat-the-market-again-2024/?source=iedfolrf0000001 Dec 22, 2023 - I wouldn't bet against it. 0

https://www.zacks.com/stock/news/2201371/should-ishares-msci-usa-min-vol-factor-etf-usmv-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2201371 Dec 22, 2023 - Style Box ETF report for USMV 0

https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/?source=iedfolrf0000001 Dec 21, 2023 - Which weight-loss stocks are good buys today? 0

https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201005 Dec 21, 2023 - With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024. 0

https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001 Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector. 0

https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316 Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024. 0

https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988 Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight. 0